Completed PHASE2 INTERVENTIONAL 2-arm NCT01873157

Bortezomib in Late Antibody-mediated Kidney Transplant Rejection (BORTEJECT)

Bortezomib in Late Antibody-mediated Kidney Transplant Rejection (BORTEJECT Study)

Sponsor: Medical University Innsbruck

Conditions Antibody-mediated Rejection Late Rejection of Renal Transplant

Updated 6 times since 2017 Last updated: Mar 22, 2017 Started: Dec 31, 2013 Primary completion: Feb 28, 2015 Completion: Feb 28, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01873157, this PHASE2 trial focuses on Antibody-mediated Rejection and Late Rejection of Renal Transplant and remains completed. Sponsored by Medical University Innsbruck, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Apr 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Apr 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical University Innsbruck
Medical University of Vienna

Data source: Medical University of Vienna

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria